Systematic review of incidence and complications of herpes zoster: towards a global perspective

Kosuke Kawai, Berhanu G Gebremeskel, Camilo J Acosta, Kosuke Kawai, Berhanu G Gebremeskel, Camilo J Acosta

Abstract

Objective: The objective of this study was to characterise the incidence rates of herpes zoster (HZ), also known as shingles, and risk of complications across the world.

Design: We systematically reviewed studies examining the incidence rates of HZ, temporal trends of HZ, the risk of complications including postherpetic neuralgia (PHN) and HZ-associated hospitalisation and mortality rates in the general population. The literature search was conducted using PubMed, EMBASE and the WHO library up to December 2013.

Results: We included 130 studies conducted in 26 countries. The incidence rate of HZ ranged between 3 and 5/1000 person-years in North America, Europe and Asia-Pacific, based on studies using prospective surveillance, electronic medical record data or administrative data with medical record review. A temporal increase in the incidence of HZ was reported in the past several decades across seven countries, often occurring before the introduction of varicella vaccination programmes. The risk of developing PHN varied from 5% to more than 30%, depending on the type of study design, age distribution of study populations and definition. More than 30% of patients with PHN experienced persistent pain for more than 1 year. The risk of recurrence of HZ ranged from 1% to 6%, with long-term follow-up studies showing higher risk (5-6%). Hospitalisation rates ranged from 2 to 25/100 000 person-years, with higher rates among elderly populations.

Conclusions: HZ is a significant global health burden that is expected to increase as the population ages. Future research with rigorous methods is important.

Keywords: EPIDEMIOLOGY; VIROLOGY.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
Study selection.
Figure 2
Figure 2
Age-specific incidence rate of herpes zoster in North America, Europe and Asia-Pacific.

References

    1. Cohen JI. Clinical practice: herpes zoster. N Engl J Med 2013;369:255–63
    1. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007;44(Suppl 1):S1–26
    1. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341–9
    1. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965;58:9–20
    1. Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010;8:37.
    1. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–84
    1. World Population Prospects: The 2012 Revision. United Nations, Department of Economic and Social Affairs, Population Division, 2013
    1. World report on disability. World Health Organization and the World Bank, 2011
    1. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004;4:26–33
    1. Araújo LQ, Macintyre CR, Vujacich C. Epidemiology and burden of herpes zoster and post-herpetic neuralgia in Australia, Asia and South America. Herpes 2007;14(Suppl 2):40–4
    1. Pinchinat S, Cebrián-Cuenca AM, Bricout H, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013;13:170.
    1. Ragozzino MW, Melton LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982;61:310–16
    1. Donahue JG, Choo PW, Manson JE, et al. The incidence of herpes zoster. Arch Intern Med 1995;155:1605–9
    1. Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005;20:748–53
    1. Mullooly JP, Riedlinger K, Chun C, et al. Incidence of herpes zoster, 1997–2002. Epidemiol Infect 2005;133:245–53
    1. Yih WK, Brooks DR, Lett SM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health 2005;5:68.
    1. Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. J Infect Dis 2005;191:2002–7
    1. Rimland D, Moanna A. Increasing incidence of herpes zoster among veterans. Clin Infect Dis 2010;50:1000–5
    1. Leung J, Harpaz R, Molinari NA, et al. Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin Infect Dis 2011;52:332–40
    1. Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011;305:160–6
    1. Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med 2013;10:e1001420.
    1. Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection 2014;42:325–34
    1. Hales CM, Harpaz R, Joesoef MR, et al. Examination of links between herpes zoster incidence and childhood varicella vaccination. Ann Intern Med 2013;159:739–45
    1. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001;127:305–14
    1. Russell ML, Schopflocher DP, Svenson L, et al. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect 2007;135:908–13
    1. Edgar BL, Galanis E, Kay C, et al. The burden of varicella and zoster in British Columbia 1994–2003: baseline assessment prior to universal vaccination. Can Commun Dis Rep 2007;33: 1–15
    1. Tanuseputro P, Zagorski B, Chan KJ, et al. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine 2011;29:8580–4
    1. Russell ML, Dover DC, Simmonds KA, et al. Shingles in Alberta: before and after publicly funded varicella vaccination. Vaccine 2013. 10.1016/j.vaccine.2013.09.018. [Epub ahead of print 4 Oct 2013].
    1. Ross CA, Brown WK, Clarke A, et al. Herpes zoster in general practice. J R Coll Gen Pract 1975;25:29–32
    1. Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 2003;70(Suppl 1):S9–14
    1. Fleming DM, Cross KW, Cobb WA, et al. Gender difference in the incidence of shingles. Epidemiol Infect 2004;132:1–5
    1. Chapman RS, Cross KW, Fleming DM. The incidence of shingles and its implications for vaccination policy. Vaccine 2003;21: 2541–7
    1. Scott FT, Leedham-Green ME, Barrett-Muir WY, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003;70(Suppl 1):S24–30
    1. Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009;137:38–47
    1. Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001;33:62–9
    1. Czernichow S, Dupuy A, Flahault A, et al. [Herpes zoster: incidence study among “sentinel” general practitioners]. Ann Dermatol Venereol 2001;128:497–501
    1. Gonzalez Chiappe S, Sarazin M, Turbelin C, et al. Herpes zoster: burden of disease in France. Vaccine 2010;28:7933–8
    1. Mick G, Gallais JL, Simon F, et al. [Burden of herpes zoster and postherpetic neuralgia: incidence, proportion, and associated costs in the French population aged 50 or over]. Rev Epidemiol Sante Publique 2010;58:393–401
    1. Paul E, Thiel T. [Epidemiology of varicella zoster infection. Results of a prospective study in the Ansbach area]. Hautarzt 1996;47:604–9
    1. Schiffner-Rohe J, Jow S, Lilie HM, et al. [Herpes zoster in Germany. A retrospective analyse of SHL data] MMW Fortschr Med 2010;151(Suppl 4):193–7
    1. Ultsch B, Siedler A, Rieck T, et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis 2011;11:173.
    1. Ultsch B, Köster I, Reinhold T, et al. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ 2013;14:1015–26
    1. Opstelten W, Mauritz JW, de Wit NJ, et al. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002;19:471–5
    1. de Melker H, Berbers G, Hahné S, et al. The epidemiology of varicella and herpes zoster in the Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006;24:3946–52
    1. Opstelten W, Van Essen GA, Schellevis F, et al. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol 2006;16:692–5
    1. Pierik JG, Gumbs PD, Fortanier SA, et al. Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. BMC Infect Dis 2012;12:110.
    1. Richard J-L, Zimmermann H. Herpès zoster 1998–2001. Sentinella-Jahresbericht; 2001
    1. Bilcke J, Ogunjimi B, Marais C, et al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect 2012;140:2096–109
    1. Pérez-Farinós N, Ordobás M, García-Fernández C, et al. Varicella and herpes zoster in Madrid, based on the Sentinel General Practitioner Network: 1997–2004. BMC Infect Dis 2007;7:59.
    1. García Cenoz M, Castilla J, Montes Y, et al. [Varicella and herpes zoster incidence prior to the introduction of systematic child vaccination in Navarre, 2005–2006]. An Sist Sanit Navar 2008;31:71–80
    1. Cebrián-Cuenca AM, Díez-Domingo J, Rodríguez MS, et al. Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain). BMC Fam Pract 2010;11:33.
    1. Morant-Talamante N, Diez-Domingo J, Martínez-Úbeda S, et al. Herpes zoster surveillance using electronic databases in the Valencian community (Spain). BMC Infect Dis 2013;13:463.
    1. Esteban-Vasallo MD, Gil-Prieto R, Domínguez-Berjón MF, et al. Temporal trends in incidence rates of herpes zoster among patients treated in primary care centers in Madrid (Spain), 2005–2012. J Infect 2014;68:378–86
    1. di Luzio Paparatti U, Arpinelli F, Visonà G. Herpes zoster and its complications in Italy: an observational survey. J Infect 1999;38:116–20
    1. Di Legami V, Gianino MM, Ciofi degli Atti M, et al. Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine 2007;25:7598–604
    1. Gialloreti LE, Merito M, Pezzotti P, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis 2010;10:230.
    1. Helgason S, Sigurdsson J, Gudmundsson S. The clinical course of herpes zoster: a prospective study in primary care. Eur J Gen Pract 1996;2:12–16
    1. Studahl M, Petzold M, Cassel T. Disease burden of herpes zoster in Sweden—predominance in the elderly and in women—a register based study. BMC Infect Dis 2013;13:586.
    1. Lionis CD, Vardavas CI, Symvoulakis EK, et al. Measuring the burden of herpes zoster and post herpetic neuralgia within primary care in rural Crete, Greece. BMC Fam Pract 2011;12:136.
    1. Weitzman D, Shavit O, Stein M, et al. A population based study of the epidemiology of Herpes Zoster and its complications. J Infect 2013;67:463–9
    1. Alakloby OM, AlJabre SH, Randhawa MA, et al. Herpes zoster in eastern Saudi Arabia: clinical presentation and management. J Drugs Dermatol 2008;7:457–62
    1. Stein AN, Britt H, Harrison C, et al. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 2009;27:520–9
    1. Jih JS, Chen YJ, Lin MW, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol 2009;89:612–16
    1. Lin YH, Huang LM, Chang IS, et al. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine 2010;28:1217–20
    1. Chao DY, Chien YZ, Yeh YP, et al. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000–2008. Epidemiol Infect 2012;140: 1131–40
    1. Park S, Kim J, Kim C, et al. A clinical study on herpes zoster during the last 10-year-period (1994–2003). Korean J Dermatol 2004;42:1531–5
    1. Choi WS, Noh JY, Huh JY, et al. Disease burden of herpes zoster in Korea. J Clin Virol 2010;47:325–9
    1. Toyama N, Shiraki K; Society of the Miyazaki Prefecture Dermatologists. Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol 2009;81:2053–8
    1. Vujacich C, Poggi E, Cecchini D, et al. [Clinical and epidemiological aspects of herpes zoster]. Medicina (B Aires) 2008;68:125–8
    1. Castro L, Chen S. Zoster: mais frequentes entre jovens que entre idosos/zoster: is more frequent among youngers than aged. An Bras Dermatol 1990;65:129–33
    1. Gaitan M. Herpes zoster y cancer: relaciones entre estas dos enfermedades/herpes zoster and cancer: relationship between these 2 diseases. Acta Med Colomb 1981;6:287–93
    1. Patel MS, Gebremariam A, Davis MM. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infect Control Hosp Epidemiol 2008;29:1157–63
    1. Jackson LA, Reynolds MA, Harpaz R. Hospitalizations to treat herpes zoster in older adults: causes and validated rates. Clin Infect Dis 2008;47:754–9
    1. Civen R, Chaves SS, Jumaan A, et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J 2009;28:954–9
    1. Yawn B, Wollan P, Bialek S, et al. Trends in herpes zoster prevalence in a population based cohort from 1945 to 2008. 48th Annual Meeting of the Infectious Diseases Society of America 2010
    1. MacIntyre CR, Chu CP, Burgess MA. Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol Infect 2003;131:675–82
    1. Carville KS, Riddell MA, Kelly HA. A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia. Vaccine 2010;28:2532–8
    1. Nelson MR, Britt HC, Harrison CM. Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. Med J Aust 2010;193:110–13
    1. Jardine A, Conaty SJ, Vally H. Herpes zoster in Australia: evidence of increase in incidence in adults attributable to varicella immunization? Epidemiol Infect 2011;139:658–65
    1. Wu PY, Wu HD, Chou TC, et al. Varicella vaccination alters the chronological trends of herpes zoster and varicella. PLoS ONE 2013;8:e77709.
    1. Galil K, Choo PW, Donahue JG, et al. The sequelae of herpes zoster. Arch Intern Med 1997;157:1209–13
    1. Thyregod HG, Rowbotham MC, Peters M, et al. Natural history of pain following herpes zoster. Pain 2007;128:148–56
    1. Klompas M, Kulldorff M, Vilk Y, et al. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc 2011;86:1146–53
    1. Katz J, McDermott MP, Cooper EM, et al. Psychosocial risk factors for postherpetic neuralgia: a prospective study of patients with herpes zoster. J Pain 2005;6:782–90
    1. Drolet M, Brisson M, Schmader K, et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain 2010;11:1211–21
    1. Jung BF, Johnson RW, Griffin DR, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004;62:1545–51
    1. Coen PG, Scott F, Leedham-Green M, et al. Predicting and preventing post-herpetic neuralgia: are current risk factors useful in clinical practice? Eur J Pain 2006;10:695–700
    1. Bouhassira D, Chassany O, Gaillat J, et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain 2012;153:342–9
    1. Meister W, Neiss A, Gross G, et al. A prognostic score for postherpetic neuralgia in ambulatory patients. Infection 1998;26:359–63
    1. Weinke T, Edte A, Schmitt S, et al. Impact of herpes zoster and post-herpetic neuralgia on patients’ quality of life: a patient-reported outcomes survey. Z Gesundh Wiss 2010;18:367–74
    1. Opstelten W, Zuithoff NP, van Essen GA, et al. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain 2007;132(Suppl 1):S52–9
    1. Sicras-Mainar A, Navarro-Artieda R, Ibáñez-Nolla J, et al. [Incidence, resource use and costs associated with postherpetic neuralgia: a population-based retrospective study]. Rev Neurol 2012;55:449–61
    1. Cebrián-Cuenca AM, Díez-Domingo J, San-Martín-Rodríguez M, et al. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. BMC Infect Dis 2011;11:302.
    1. Volpi A, Gatti A, Pica F, et al. Clinical and psychosocial correlates of post-herpetic neuralgia. J Med Virol 2008;80:1646–52
    1. Parruti G, Tontodonati M, Rebuzzi C, et al. Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapy. BMC Med 2010;8:58.
    1. Bricout H, Perinetti E, Marchettini P, et al. Predictor factors for the presence of post herpetic neuralgia at 3 months in herpes zoster patients aged 50 and over in Italy: results from a gp-based observational prospective multicenter study. Value Health 2013;16:A343
    1. Helgason S, Petursson G, Gudmundsson S, et al. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000;321:794–6
    1. Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. J Public Health(Germany) 2012;20:441–51
    1. Tsai TF, Yu HS, Rampakakis E, et al. Assessment of burden of illness due to herpes zoster and predictors of outcomes in Taiwan: a prospective observational study. Int J Infect Dis 2012;16:e115
    1. Kurokawa I, Kumano K, Murakawa K, et al. Clinical correlates of prolonged pain in Japanese patients with acute herpes zoster. J Int Med Res 2002;30:56–65
    1. Kurokawa I, Murakawa K, Kumano K. The change in zoster-associated pain treated with oral valaciclovir in immunocompetent patients with acute herpes zoster. Int J Clin Pract 2007;61:1223–9
    1. Kanbayashi Y, Onishi K, Fukazawa K, et al. Predictive factors for postherpetic neuralgia using ordered logistic regression analysis. Clin J Pain 2012;28:712–14
    1. Ro BI, Go JW, Kim SH, et al. A clinical study on 2096 patients with herpes zoster during the four-year-period (2007–2011). J Dermatol 2012;39:10
    1. Song HJ, Choi WS, Lee JD, et al. Measuring herpes zoster and post-herpetic neuralgia associated burden of illness and health care utilization and costs in Korea: a clinical epidemiological study. Int J Infect Dis 2012;16:e111
    1. Cho SI, Lee CH, Park GH, et al. Use of S-LANSS, a tool for screening neuropathic pain, for predicting postherpetic neuralgia in patients after acute herpes zoster events: a single-center, 12-month, prospective cohort study. J Pain 2014;15:149–56
    1. Tunsuriyawong S, Puavilai S. Herpes zoster, clinical course and associated diseases: a 5-year retrospective study at Tamathibodi Hospital. J Med Assoc Thai 2005;88:678–81
    1. Aunhachoke K, Bussaratid V, Chirachanakul P, et al. Measuring herpes zoster, zoster-associated pain, post-herpetic neuralgia-associated loss of quality of life, and healthcare utilization and costs in Thailand. Int J Dermatol 2011;50:428–35
    1. Goh CL, Khoo L. A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. Int J Dermatol 1997;36:667–72
    1. Chaudhary SD, Dashore A, Pahwa US. A clinico-epidemiologic profile of herpes zoster in North India. Indian J Dermatol Venereol Leprol 1987;53:213–16
    1. Abdul Latheef EN, Pavithran K. Herpes zoster: a clinical study in 205 patients. Indian J Dermatol 2011;56:529–32
    1. Vujacich C, De Wouters L, Margari A, et al. Assessment of burden of illness due to herpes zoster in Argentina: a prospective observational study. Value Health 2013;16:A668
    1. Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005;6:356–63
    1. Reda H, Greene K, Rice FL, et al. Natural history of herpes zoster: late follow-up of 3.9 years (n=43) and 7.7 years (n=10). Pain 2013;154:2227–33
    1. Watson CP, Oaklander AL. Postherpetic neuralgia. Pain Pract 2002;2:295–307
    1. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975;25:571–5
    1. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999;3:335–42
    1. McKendrick MW, Ogan P, Care CC. A 9 year follow up of post herpetic neuralgia and predisposing factors in elderly patients following herpes zoster. J Infect 2009;59:416–20
    1. van Seventer R, Sadosky A, Lucero M, et al. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006;35:132–7
    1. Epstein E. Recurrences in herpes zoster. Cutis 1980;26: 378–9
    1. Yawn BP, Wollan PC, Kurland MJ, et al. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011;86:88–93
    1. Jeong S, Kim I. Recurrence rate of herpes zoster during the previous decade. Korean J Dermatol 2012;50:287–9
    1. Tseng HF, Chi M, Smith N, et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis 2012;206:190–6
    1. Ghaznawi N, Virdi A, Dayan A, et al. Herpes zoster ophthalmicus: comparison of disease in patients 60 years and older versus younger than 60 years. Ophthalmology 2011;118:2242–50
    1. Borkar DS, Tham VM, Esterberg E, et al. Incidence of herpes zoster ophthalmicus: results from the pacific ocular inflammation study. Ophthalmology 2013;120:451–6
    1. Bayu S, Alemayehu W. Clinical profile of herpes zoster ophthalmicus in Ethiopians. Clin Infect Dis 1997;24:1256–60
    1. Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology 2008;115(Suppl 2):S3–12
    1. Zaal MJ, Völker-Dieben HJ, D'Amaro J. Visual prognosis in immunocompetent patients with herpes zoster ophthalmicus. Acta Ophthalmol Scand 2003;81:216–20
    1. Womack LW, Liesegang TJ. Complications of herpes zoster ophthalmicus. Arch Ophthalmol 1983;101:42–5
    1. Harding SP, Lipton JR, Wells JC. Natural history of herpes zoster ophthalmicus: predictors of postherpetic neuralgia and ocular involvement. Br J Ophthalmol 1987;71:353–8
    1. Yawn BP, Wollan PC, St Sauver JL, et al. Herpes zoster eye complications: rates and trends. Mayo Clin Proc 2013;88: 562–70
    1. Lin F, Hadler JL. Epidemiology of primary varicella and herpes zoster hospitalizations: the pre-varicella vaccine era. J Infect Dis 2000;181:1897–905
    1. Coplan P, Black S, Rojas C, et al. Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. Pediatr Infect Dis J 2001;20:641–5
    1. Gil A, San-Martín M, Carrasco P, et al. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 2004;22: 3947–51
    1. Gil A, Gil R, Alvaro A, et al. Burden of herpes zoster requiring hospitalization in Spain during a seven-year period (1998–2004). BMC Infect Dis 2009;9:55.
    1. Bayas JM, Gil R, Llupia A, et al. Hospitalizations due to herpes zoster and postherpetic neuralgia in Catalonia, 1998–2003. Vacunas 2011;12:122–8
    1. Gil-Prieto R, Walter S, Gonzalez-Escalada A, et al. Different vaccination strategies in Spain and its impact on severe varicella and zoster. Vaccine 2014;32:277–83
    1. Mesquita M, Froes F. Hospital admissions for herpes zoster in Portugal between 2000 and 2010. Acta Med Port 2013;26:531–6
    1. Mahamud A, Marin M, Nickell SP, et al. Herpes zoster-related deaths in the United States: validity of death certificates and mortality rates, 1979–2007. Clin Infect Dis 2012;55:960–6
    1. Yawn BP, Wollan P, St Sauver J. Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? Am J Epidemiol 2011;174:1054–61
    1. Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health 1998;3:886–90
    1. Vergara-Castañeda A, Escobar-Gutiérrez A, Ruiz-Tovar K, et al. Epidemiology of varicella in Mexico. J Clin Virol 2012;55:51–7
    1. Nagasako EM, Johnson RW, Griffin DR, et al. Geographic and racial aspects of herpes zoster. J Med Virol 2003;70(Suppl 1):S20–3
    1. Schmidt-Chanasit J, Sauerbrei A. Evolution and world-wide distribution of varicella-zoster virus clades. Infect Genet Evol 2011;11:1–10
    1. Loparev VN, Gonzalez A, Deleon-Carnes M, et al. Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping. J Virol 2004;78:8349–58
    1. Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis 1995;1:7–15
    1. Sengupta N, Taha Y, Scott FT, et al. Varicella-zoster-virus genotypes in East London: a prospective study in patients with herpes zoster. J Infect Dis 2007;196:1014–20
    1. Sauerbrei A, Wutzler P. Different genotype pattern of varicella-zoster virus obtained from patients with varicella and zoster in Germany. J Med Virol 2007;79:1025–31
    1. Wahrendorf M, Reinhardt JD, Siegrist J. Relationships of disability with age among adults aged 50 to 85: evidence from the United States, England and continental Europe. PLoS ONE 2013;8:e71893.
    1. Johnson RW, Wasner G, Saddier P, et al. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother 2007;7:1581–95
    1. Dworkin RH, Carrington D, Cunningham A, et al. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antiviral Res 1997;33:73–85
    1. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004;5:344–56

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する